禽甲型流感（H7N9）ValuPanel™试剂*是ValuPanel系列检测试剂的一部分。ValuPanel试剂由检测不同病原菌株遗传信号的探针和引物组成，能够区分在2013年流行的导致禽流感并能够感染人类的禽流感H7N9病毒。这种病毒不同于早期的禽流感病毒株H5N1和仅在鸟类中发现的禽流感病毒株。 该Panel由双标记BHQ探针组成，用于qPCR实验中，以区分H7N9病毒株。这个新的ValuPanel包含以下几种基因的探针和引物： 通用甲型流感病毒 甲型流感病毒亚型H7和N9 人类RNase P（提取对照） H7和N9亚型的寡核苷酸序列由世界卫生组织（WHO）在中国国家流感中心（CNIC）的流感备案和研究合作中心设计。通用甲型流感和RNase P序列由美国疾病控制和预防中心（CDC**）设计并获得许可。N9亚型的正向和反向引物序列用的是2013年4月15日的修订方案中列出的CNIC-WHO的优化序列。所有探针用FAM和Black Hole Quencher（BHQ）染料标记，且采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 *仅供研究使用。不用于诊断程序。 ** CDC不认可产品或服务。 Avian Influenza A (H7N9) ValuPanel™ Reagents* are now part of the ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These signatures discriminate the H7N9 virus that causes avian (bird) flu, and capable of infecting humans when circulating in 2013. This virus differs from earlier avian flu strains including H5N1, and others found only in birds. This panel consists of dual-labeled BHQ® probes for use in real-time qPCR to discriminate H7N9 viral strains. This new ValuPanel contains probes and primers based on genetic signatures for the following: Universal Influenza A Influenza A subtypes H7 and N9 Human RNase P (Extraction Control) Oligonucleotide sequences for the H7 and N9 subtypes were designed by the World Health Organization (WHO) Collaborating Center for Reference and Research on Influenza at the Chinese National Influenza Center (CNIC) in Beijing, China. Universal Influenza A and RNase P sequences were designed by and licensed from the US Centers for Disease Control and Prevention (CDC**). Sequences for the forward and reverse primers for the N9 subtype correspond to the CNIC-WHO’s optimized sequences as listed in the revised protocol dated April 15th, 2013. All probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes, and are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes included in the Avian Influenza A (H7N9) panel. *For Research Use Only. Not for use in diagnostic procedures. **CDC does not endorse products or services.

禽甲型流感（H7N9）ValuPanel™试剂*是ValuPanel系列检测试剂的一部分。ValuPanel试剂由检测不同病原菌株遗传信号的探针和引物组成，能够区分在2013年流行的导致禽流感并能够感染人类的禽流感H7N9病毒。这种病毒不同于早期的禽流感病毒株H5N1和仅在鸟类中发现的禽流感病毒株。 该Panel由双标记BHQ探针组成，用于qPCR实验中，以区分H7N9病毒株。这个新的ValuPanel包含以下几种基因的探针和引物： 通用甲型流感病毒 甲型流感病毒亚型H7和N9 人类RNase P（提取对照） H7和N9亚型的寡核苷酸序列由世界卫生组织（WHO）在中国国家流感中心（CNIC）的流感备案和研究合作中心设计。通用甲型流感和RNase P序列由美国疾病控制和预防中心（CDC**）设计并获得许可。N9亚型的正向和反向引物序列用的是2013年4月15日的修订方案中列出的CNIC-WHO的优化序列。所有探针用FAM和Black Hole Quencher（BHQ）染料标记，且采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 *仅供研究使用。不用于诊断程序。 ** CDC不认可产品或服务。 Avian Influenza A (H7N9) ValuPanel™ Reagents* are now part of the ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These signatures discriminate the H7N9 virus that causes avian (bird) flu, and capable of infecting humans when circulating in 2013. This virus differs from earlier avian flu strains including H5N1, and others found only in birds. This panel consists of dual-labeled BHQ® probes for use in real-time qPCR to discriminate H7N9 viral strains. This new ValuPanel contains probes and primers based on genetic signatures for the following: Universal Influenza A Influenza A subtypes H7 and N9 Human RNase P (Extraction Control) Oligonucleotide sequences for the H7 and N9 subtypes were designed by the World Health Organization (WHO) Collaborating Center for Reference and Research on Influenza at the Chinese National Influenza Center (CNIC) in Beijing, China. Universal Influenza A and RNase P sequences were designed by and licensed from the US Centers for Disease Control and Prevention (CDC**). Sequences for the forward and reverse primers for the N9 subtype correspond to the CNIC-WHO’s optimized sequences as listed in the revised protocol dated April 15th, 2013. All probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes, and are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes included in the Avian Influenza A (H7N9) panel. *For Research Use Only. Not for use in diagnostic procedures. **CDC does not endorse products or services.

ValuPanel™试剂*由RT-qPCR的探针和引物组成，用于不同病原菌株的遗传鉴定。 *仅供研究使用。不用于诊断程序。 获CDC授权的甲型流感病毒亚型鉴定** 作为被授权的鉴定甲型流感亚型（季节性流感）的寡核苷酸制造商，LGC Biosearch提供所有主要流感病毒株的检测鉴定试剂，这些试剂Panel由用于qPCR的双标记BHQ探针、正向引物和反向引物组成，能够区分不同流感亚型的序列。甲型流感ValuPanel试剂含有基于以下菌株的遗传鉴定的探针和引物： 甲型（A）流感和乙型（B）流感 甲型流感亚型H1、H3和H5 人类RNase P（提取对照） 这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物均采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 ** CDC不认可产品或服务。 ValuPanel™ Reagents are composed of probes and primers for RT-qPCR to resolve the genetic signatures of different pathogen strains. LGC Biosearch Technologies is pleased to introduce Influenza A subtyping to the catalog of ValuPanel Reagents*. *For Research Use Only. Not for use in diagnostic procedures. Influenza A Subtyping Signatures Licensed from the CDC** As a licensed manufacturer of oligonucleotides to resolve influenza A subtypes (seasonal flu), LGC Biosearch is pleased to provide these important reagents for the detection of all major strains of influenza. This panel consists of dual-labeled BHQ® probes, a forward primer, and a reverse primer for use in real-time qPCR, to discriminate the sequences of influenza subtypes. Influenza A ValuPanel Reagents contain probes and primers based on genetic signatures for the following strains: Influenza A and Influenza B Influenza A subtypes H1, H3, and H5 Human RNase P (Extraction Control) These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the Influenza A subtyping panel. **CDC does not endorse products or services.

ValuPanel™试剂*由RT-qPCR的探针和引物组成，用于不同病原菌株的遗传鉴定。 *仅供研究使用。不用于诊断程序。 获CDC授权的甲型流感病毒亚型鉴定** 作为被授权的鉴定甲型流感亚型（季节性流感）的寡核苷酸制造商，LGC Biosearch提供所有主要流感病毒株的检测鉴定试剂，这些试剂Panel由用于qPCR的双标记BHQ探针、正向引物和反向引物组成，能够区分不同流感亚型的序列。甲型流感ValuPanel试剂含有基于以下菌株的遗传鉴定的探针和引物： 甲型（A）流感和乙型（B）流感 甲型流感亚型H1、H3和H5 人类RNase P（提取对照） 这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物均采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 ** CDC不认可产品或服务。 ValuPanel™ Reagents are composed of probes and primers for RT-qPCR to resolve the genetic signatures of different pathogen strains. LGC Biosearch Technologies is pleased to introduce Influenza A subtyping to the catalog of ValuPanel Reagents*. *For Research Use Only. Not for use in diagnostic procedures. Influenza A Subtyping Signatures Licensed from the CDC** As a licensed manufacturer of oligonucleotides to resolve influenza A subtypes (seasonal flu), LGC Biosearch is pleased to provide these important reagents for the detection of all major strains of influenza. This panel consists of dual-labeled BHQ® probes, a forward primer, and a reverse primer for use in real-time qPCR, to discriminate the sequences of influenza subtypes. Influenza A ValuPanel Reagents contain probes and primers based on genetic signatures for the following strains: Influenza A and Influenza B Influenza A subtypes H1, H3, and H5 Human RNase P (Extraction Control) These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the Influenza A subtyping panel. **CDC does not endorse products or services.

禽甲型流感（H7N9）ValuPanel™试剂*是ValuPanel系列检测试剂的一部分。ValuPanel试剂由检测不同病原菌株遗传信号的探针和引物组成，能够区分在2013年流行的导致禽流感并能够感染人类的禽流感H7N9病毒。这种病毒不同于早期的禽流感病毒株H5N1和仅在鸟类中发现的禽流感病毒株。 该Panel由双标记BHQ探针组成，用于qPCR实验中，以区分H7N9病毒株。这个新的ValuPanel包含以下几种基因的探针和引物： 通用甲型流感病毒 甲型流感病毒亚型H7和N9 人类RNase P（提取对照） H7和N9亚型的寡核苷酸序列由世界卫生组织（WHO）在中国国家流感中心（CNIC）的流感备案和研究合作中心设计。通用甲型流感和RNase P序列由美国疾病控制和预防中心（CDC**）设计并获得许可。N9亚型的正向和反向引物序列用的是2013年4月15日的修订方案中列出的CNIC-WHO的优化序列。所有探针用FAM和Black Hole Quencher（BHQ）染料标记，且采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 *仅供研究使用。不用于诊断程序。 ** CDC不认可产品或服务。 Avian Influenza A (H7N9) ValuPanel™ Reagents* are now part of the ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These signatures discriminate the H7N9 virus that causes avian (bird) flu, and capable of infecting humans when circulating in 2013. This virus differs from earlier avian flu strains including H5N1, and others found only in birds. This panel consists of dual-labeled BHQ® probes for use in real-time qPCR to discriminate H7N9 viral strains. This new ValuPanel contains probes and primers based on genetic signatures for the following: Universal Influenza A Influenza A subtypes H7 and N9 Human RNase P (Extraction Control) Oligonucleotide sequences for the H7 and N9 subtypes were designed by the World Health Organization (WHO) Collaborating Center for Reference and Research on Influenza at the Chinese National Influenza Center (CNIC) in Beijing, China. Universal Influenza A and RNase P sequences were designed by and licensed from the US Centers for Disease Control and Prevention (CDC**). Sequences for the forward and reverse primers for the N9 subtype correspond to the CNIC-WHO’s optimized sequences as listed in the revised protocol dated April 15th, 2013. All probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes, and are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes included in the Avian Influenza A (H7N9) panel. *For Research Use Only. Not for use in diagnostic procedures. **CDC does not endorse products or services.

禽甲型流感（H7N9）ValuPanel™试剂*是ValuPanel系列检测试剂的一部分。ValuPanel试剂由检测不同病原菌株遗传信号的探针和引物组成，能够区分在2013年流行的导致禽流感并能够感染人类的禽流感H7N9病毒。这种病毒不同于早期的禽流感病毒株H5N1和仅在鸟类中发现的禽流感病毒株。 该Panel由双标记BHQ探针组成，用于qPCR实验中，以区分H7N9病毒株。这个新的ValuPanel包含以下几种基因的探针和引物： 通用甲型流感病毒 甲型流感病毒亚型H7和N9 人类RNase P（提取对照） H7和N9亚型的寡核苷酸序列由世界卫生组织（WHO）在中国国家流感中心（CNIC）的流感备案和研究合作中心设计。通用甲型流感和RNase P序列由美国疾病控制和预防中心（CDC**）设计并获得许可。N9亚型的正向和反向引物序列用的是2013年4月15日的修订方案中列出的CNIC-WHO的优化序列。所有探针用FAM和Black Hole Quencher（BHQ）染料标记，且采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 *仅供研究使用。不用于诊断程序。 ** CDC不认可产品或服务。 Avian Influenza A (H7N9) ValuPanel™ Reagents* are now part of the ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These signatures discriminate the H7N9 virus that causes avian (bird) flu, and capable of infecting humans when circulating in 2013. This virus differs from earlier avian flu strains including H5N1, and others found only in birds. This panel consists of dual-labeled BHQ® probes for use in real-time qPCR to discriminate H7N9 viral strains. This new ValuPanel contains probes and primers based on genetic signatures for the following: Universal Influenza A Influenza A subtypes H7 and N9 Human RNase P (Extraction Control) Oligonucleotide sequences for the H7 and N9 subtypes were designed by the World Health Organization (WHO) Collaborating Center for Reference and Research on Influenza at the Chinese National Influenza Center (CNIC) in Beijing, China. Universal Influenza A and RNase P sequences were designed by and licensed from the US Centers for Disease Control and Prevention (CDC**). Sequences for the forward and reverse primers for the N9 subtype correspond to the CNIC-WHO’s optimized sequences as listed in the revised protocol dated April 15th, 2013. All probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes, and are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes included in the Avian Influenza A (H7N9) panel. *For Research Use Only. Not for use in diagnostic procedures. **CDC does not endorse products or services.

禽甲型流感（H7N9）ValuPanel™试剂*是ValuPanel系列检测试剂的一部分。ValuPanel试剂由检测不同病原菌株遗传信号的探针和引物组成，能够区分在2013年流行的导致禽流感并能够感染人类的禽流感H7N9病毒。这种病毒不同于早期的禽流感病毒株H5N1和仅在鸟类中发现的禽流感病毒株。 该Panel由双标记BHQ探针组成，用于qPCR实验中，以区分H7N9病毒株。这个新的ValuPanel包含以下几种基因的探针和引物： 通用甲型流感病毒 甲型流感病毒亚型H7和N9 人类RNase P（提取对照） H7和N9亚型的寡核苷酸序列由世界卫生组织（WHO）在中国国家流感中心（CNIC）的流感备案和研究合作中心设计。通用甲型流感和RNase P序列由美国疾病控制和预防中心（CDC**）设计并获得许可。N9亚型的正向和反向引物序列用的是2013年4月15日的修订方案中列出的CNIC-WHO的优化序列。所有探针用FAM和Black Hole Quencher（BHQ）染料标记，且采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 *仅供研究使用。不用于诊断程序。 ** CDC不认可产品或服务。 Avian Influenza A (H7N9) ValuPanel™ Reagents* are now part of the ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These signatures discriminate the H7N9 virus that causes avian (bird) flu, and capable of infecting humans when circulating in 2013. This virus differs from earlier avian flu strains including H5N1, and others found only in birds. This panel consists of dual-labeled BHQ® probes for use in real-time qPCR to discriminate H7N9 viral strains. This new ValuPanel contains probes and primers based on genetic signatures for the following: Universal Influenza A Influenza A subtypes H7 and N9 Human RNase P (Extraction Control) Oligonucleotide sequences for the H7 and N9 subtypes were designed by the World Health Organization (WHO) Collaborating Center for Reference and Research on Influenza at the Chinese National Influenza Center (CNIC) in Beijing, China. Universal Influenza A and RNase P sequences were designed by and licensed from the US Centers for Disease Control and Prevention (CDC**). Sequences for the forward and reverse primers for the N9 subtype correspond to the CNIC-WHO’s optimized sequences as listed in the revised protocol dated April 15th, 2013. All probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes, and are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes included in the Avian Influenza A (H7N9) panel. *For Research Use Only. Not for use in diagnostic procedures. **CDC does not endorse products or services.

ValuPanel™试剂*由RT-qPCR的探针和引物组成，用于不同病原菌株的遗传鉴定。 *仅供研究使用。不用于诊断程序。 获CDC授权的甲型流感病毒亚型鉴定** 作为被授权的鉴定甲型流感亚型（季节性流感）的寡核苷酸制造商，LGC Biosearch提供所有主要流感病毒株的检测鉴定试剂，这些试剂Panel由用于qPCR的双标记BHQ探针、正向引物和反向引物组成，能够区分不同流感亚型的序列。甲型流感ValuPanel试剂含有基于以下菌株的遗传鉴定的探针和引物： 甲型（A）流感和乙型（B）流感 甲型流感亚型H1、H3和H5 人类RNase P（提取对照） 这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物均采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 ** CDC不认可产品或服务。 ValuPanel™ Reagents are composed of probes and primers for RT-qPCR to resolve the genetic signatures of different pathogen strains. LGC Biosearch Technologies is pleased to introduce Influenza A subtyping to the catalog of ValuPanel Reagents*. *For Research Use Only. Not for use in diagnostic procedures. Influenza A Subtyping Signatures Licensed from the CDC** As a licensed manufacturer of oligonucleotides to resolve influenza A subtypes (seasonal flu), LGC Biosearch is pleased to provide these important reagents for the detection of all major strains of influenza. This panel consists of dual-labeled BHQ® probes, a forward primer, and a reverse primer for use in real-time qPCR, to discriminate the sequences of influenza subtypes. Influenza A ValuPanel Reagents contain probes and primers based on genetic signatures for the following strains: Influenza A and Influenza B Influenza A subtypes H1, H3, and H5 Human RNase P (Extraction Control) These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the Influenza A subtyping panel. **CDC does not endorse products or services.

禽甲型流感（H7N9）ValuPanel™试剂*是ValuPanel系列检测试剂的一部分。ValuPanel试剂由检测不同病原菌株遗传信号的探针和引物组成，能够区分在2013年流行的导致禽流感并能够感染人类的禽流感H7N9病毒。这种病毒不同于早期的禽流感病毒株H5N1和仅在鸟类中发现的禽流感病毒株。 该Panel由双标记BHQ探针组成，用于qPCR实验中，以区分H7N9病毒株。这个新的ValuPanel包含以下几种基因的探针和引物： 通用甲型流感病毒 甲型流感病毒亚型H7和N9 人类RNase P（提取对照） H7和N9亚型的寡核苷酸序列由世界卫生组织（WHO）在中国国家流感中心（CNIC）的流感备案和研究合作中心设计。通用甲型流感和RNase P序列由美国疾病控制和预防中心（CDC**）设计并获得许可。N9亚型的正向和反向引物序列用的是2013年4月15日的修订方案中列出的CNIC-WHO的优化序列。所有探针用FAM和Black Hole Quencher（BHQ）染料标记，且采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 *仅供研究使用。不用于诊断程序。 ** CDC不认可产品或服务。 Avian Influenza A (H7N9) ValuPanel™ Reagents* are now part of the ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These signatures discriminate the H7N9 virus that causes avian (bird) flu, and capable of infecting humans when circulating in 2013. This virus differs from earlier avian flu strains including H5N1, and others found only in birds. This panel consists of dual-labeled BHQ® probes for use in real-time qPCR to discriminate H7N9 viral strains. This new ValuPanel contains probes and primers based on genetic signatures for the following: Universal Influenza A Influenza A subtypes H7 and N9 Human RNase P (Extraction Control) Oligonucleotide sequences for the H7 and N9 subtypes were designed by the World Health Organization (WHO) Collaborating Center for Reference and Research on Influenza at the Chinese National Influenza Center (CNIC) in Beijing, China. Universal Influenza A and RNase P sequences were designed by and licensed from the US Centers for Disease Control and Prevention (CDC**). Sequences for the forward and reverse primers for the N9 subtype correspond to the CNIC-WHO’s optimized sequences as listed in the revised protocol dated April 15th, 2013. All probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes, and are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes included in the Avian Influenza A (H7N9) panel. *For Research Use Only. Not for use in diagnostic procedures. **CDC does not endorse products or services.

2009年H1N1（新型流感A）ValuPanel™试剂*是LGC Biosearch Technologies的ValuPanel检测试剂系列的一部分。ValuPanel试剂由鉴定不同病原菌株的探针和引物组成。 *仅供研究使用，不用于诊断程序 2009年H1N1鉴定获CDC授权** 作为被授权的鉴定2009 H1N1的寡核苷酸制造商，LGC Biosearch 2009 H1N1检测Panel由用于qPCR的双标记BHQ探针、正向引物和反向引物组成，能够区分H1N1相关病毒株。2009 H1N1 ValuPanel试剂含有基于以下病毒株遗传鉴定的探针和引物： 流感A 猪流感A 猪H1流感 人类RNase P（提取对照） 这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物均采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 ** CDC不认可产品或服务。 应对公共卫生紧急情况 为了响应2009年H1N1的爆发，美国食品和药物管理局（FDA）向CDC发布了紧急使用授权（EUA），立即使用美国疾病控制和预防中心（CDC）设计的qRT-PCR方法检测分析2009年H1N1。CDC很快开发了2009 H1N1Panel，以检测和识别新型流感A（H1N1）病毒的病例，并且是个面向公共卫生和其他合格实验室进行分子诊断试验的FDA授权分销商。Biosearch Technologies通过提供H1N1检测Panel所需的探针和引物参与了对流感大流行的快速反应。 世界卫生组织（WHO）在网上公布了其流感A（H1N1）qRT-PCR的CDC方案，列出了来自LGC Biosearch的Black HoleQuencher®（BHQ®-1）染料作为所有其所列探针的猝灭剂。 The 2009 H1N1 (Novel Influenza A) ValuPanel™ Reagents* are part of LGC Biosearch Technologies’ ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. *For Research Use Only. Not for use in diagnostic procedures. 2009 H1N1 Signatures Licensed from the CDC** As a licensed manufacturer of oligonucleotides to resolve 2009 H1N1 signatures, LGC Biosearch Technologies is pleased to offer the same sequences in the form of ValuPanel Reagents. This panel consists of dual-labeled BHQ probes, a forward primer, and a reverse primer for use in real-time qPCR to discriminate H1N1-related viral strains. 2009 H1N1 ValuPanel Reagents contain probes and primers based on genetic signatures for the following strains: Influenza A Swine Influenza A Swine H1 Influenza A Human RNase P (Extraction Control) These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the 2009 H1N1 diagnostic test. **CDC does not endorse products or services. Responding to a Public Health Emergency In response to the outbreak of novel 2009 H1N1, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to the CDC for the immediate use of the Real-time RT-PCR Detection Assays for 2009 H1N1 designed by the US Centers for Disease Control and Prevention (CDC). The CDC readily developed the 2009 H1N1 Panel to detect and identify cases of the novel influenza A (H1N1) virus, and is the first FDA-authorized distributor of this molecular diagnostic test to public health and other qualified laboratories. Biosearch Technologies participated in the rapid response to the Flu pandemic by supplying the probes and primers necessary for the H1N1 detection panel. Available to the public online, the World Health Organization (WHO) posted the CDC protocol of realtime RTPCR for influenza A (H1N1) which lists the Black Hole Quencher® (BHQ®-1) dye from LGC Biosearch as the quencher for all listed probes.

2009年H1N1（新型流感A）ValuPanel™试剂*是LGC Biosearch Technologies的ValuPanel检测试剂系列的一部分。ValuPanel试剂由鉴定不同病原菌株的探针和引物组成。 *仅供研究使用，不用于诊断程序 2009年H1N1鉴定获CDC授权** 作为被授权的鉴定2009 H1N1的寡核苷酸制造商，LGC Biosearch 2009 H1N1检测Panel由用于qPCR的双标记BHQ探针、正向引物和反向引物组成，能够区分H1N1相关病毒株。2009 H1N1 ValuPanel试剂含有基于以下病毒株遗传鉴定的探针和引物： 流感A 猪流感A 猪H1流感 人类RNase P（提取对照） 这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物均采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 ** CDC不认可产品或服务。 应对公共卫生紧急情况 为了响应2009年H1N1的爆发，美国食品和药物管理局（FDA）向CDC发布了紧急使用授权（EUA），立即使用美国疾病控制和预防中心（CDC）设计的qRT-PCR方法检测分析2009年H1N1。CDC很快开发了2009 H1N1Panel，以检测和识别新型流感A（H1N1）病毒的病例，并且是个面向公共卫生和其他合格实验室进行分子诊断试验的FDA授权分销商。Biosearch Technologies通过提供H1N1检测Panel所需的探针和引物参与了对流感大流行的快速反应。 世界卫生组织（WHO）在网上公布了其流感A（H1N1）qRT-PCR的CDC方案，列出了来自LGC Biosearch的Black HoleQuencher®（BHQ®-1）染料作为所有其所列探针的猝灭剂。 The 2009 H1N1 (Novel Influenza A) ValuPanel™ Reagents* are part of LGC Biosearch Technologies’ ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. *For Research Use Only. Not for use in diagnostic procedures. 2009 H1N1 Signatures Licensed from the CDC** As a licensed manufacturer of oligonucleotides to resolve 2009 H1N1 signatures, LGC Biosearch Technologies is pleased to offer the same sequences in the form of ValuPanel Reagents. This panel consists of dual-labeled BHQ probes, a forward primer, and a reverse primer for use in real-time qPCR to discriminate H1N1-related viral strains. 2009 H1N1 ValuPanel Reagents contain probes and primers based on genetic signatures for the following strains: Influenza A Swine Influenza A Swine H1 Influenza A Human RNase P (Extraction Control) These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the 2009 H1N1 diagnostic test. **CDC does not endorse products or services. Responding to a Public Health Emergency In response to the outbreak of novel 2009 H1N1, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to the CDC for the immediate use of the Real-time RT-PCR Detection Assays for 2009 H1N1 designed by the US Centers for Disease Control and Prevention (CDC). The CDC readily developed the 2009 H1N1 Panel to detect and identify cases of the novel influenza A (H1N1) virus, and is the first FDA-authorized distributor of this molecular diagnostic test to public health and other qualified laboratories. Biosearch Technologies participated in the rapid response to the Flu pandemic by supplying the probes and primers necessary for the H1N1 detection panel. Available to the public online, the World Health Organization (WHO) posted the CDC protocol of realtime RTPCR for influenza A (H1N1) which lists the Black Hole Quencher® (BHQ®-1) dye from LGC Biosearch as the quencher for all listed probes.

2009年H1N1（新型流感A）ValuPanel™试剂*是LGC Biosearch Technologies的ValuPanel检测试剂系列的一部分。ValuPanel试剂由鉴定不同病原菌株的探针和引物组成。 *仅供研究使用，不用于诊断程序 2009年H1N1鉴定获CDC授权** 作为被授权的鉴定2009 H1N1的寡核苷酸制造商，LGC Biosearch 2009 H1N1检测Panel由用于qPCR的双标记BHQ探针、正向引物和反向引物组成，能够区分H1N1相关病毒株。2009 H1N1 ValuPanel试剂含有基于以下病毒株遗传鉴定的探针和引物： 流感A 猪流感A 猪H1流感 人类RNase P（提取对照） 这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物均采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 ** CDC不认可产品或服务。 应对公共卫生紧急情况 为了响应2009年H1N1的爆发，美国食品和药物管理局（FDA）向CDC发布了紧急使用授权（EUA），立即使用美国疾病控制和预防中心（CDC）设计的qRT-PCR方法检测分析2009年H1N1。CDC很快开发了2009 H1N1Panel，以检测和识别新型流感A（H1N1）病毒的病例，并且是个面向公共卫生和其他合格实验室进行分子诊断试验的FDA授权分销商。Biosearch Technologies通过提供H1N1检测Panel所需的探针和引物参与了对流感大流行的快速反应。 世界卫生组织（WHO）在网上公布了其流感A（H1N1）qRT-PCR的CDC方案，列出了来自LGC Biosearch的Black HoleQuencher®（BHQ®-1）染料作为所有其所列探针的猝灭剂。 The 2009 H1N1 (Novel Influenza A) ValuPanel™ Reagents* are part of LGC Biosearch Technologies’ ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. *For Research Use Only. Not for use in diagnostic procedures. 2009 H1N1 Signatures Licensed from the CDC** As a licensed manufacturer of oligonucleotides to resolve 2009 H1N1 signatures, LGC Biosearch Technologies is pleased to offer the same sequences in the form of ValuPanel Reagents. This panel consists of dual-labeled BHQ probes, a forward primer, and a reverse primer for use in real-time qPCR to discriminate H1N1-related viral strains. 2009 H1N1 ValuPanel Reagents contain probes and primers based on genetic signatures for the following strains: Influenza A Swine Influenza A Swine H1 Influenza A Human RNase P (Extraction Control) These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the 2009 H1N1 diagnostic test. **CDC does not endorse products or services. Responding to a Public Health Emergency In response to the outbreak of novel 2009 H1N1, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to the CDC for the immediate use of the Real-time RT-PCR Detection Assays for 2009 H1N1 designed by the US Centers for Disease Control and Prevention (CDC). The CDC readily developed the 2009 H1N1 Panel to detect and identify cases of the novel influenza A (H1N1) virus, and is the first FDA-authorized distributor of this molecular diagnostic test to public health and other qualified laboratories. Biosearch Technologies participated in the rapid response to the Flu pandemic by supplying the probes and primers necessary for the H1N1 detection panel. Available to the public online, the World Health Organization (WHO) posted the CDC protocol of realtime RTPCR for influenza A (H1N1) which lists the Black Hole Quencher® (BHQ®-1) dye from LGC Biosearch as the quencher for all listed probes.

2009年H1N1（新型流感A）ValuPanel™试剂*是LGC Biosearch Technologies的ValuPanel检测试剂系列的一部分。ValuPanel试剂由鉴定不同病原菌株的探针和引物组成。 *仅供研究使用，不用于诊断程序 2009年H1N1鉴定获CDC授权** 作为被授权的鉴定2009 H1N1的寡核苷酸制造商，LGC Biosearch 2009 H1N1检测Panel由用于qPCR的双标记BHQ探针、正向引物和反向引物组成，能够区分H1N1相关病毒株。2009 H1N1 ValuPanel试剂含有基于以下病毒株遗传鉴定的探针和引物： 流感A 猪流感A 猪H1流感 人类RNase P（提取对照） 这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物均采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 ** CDC不认可产品或服务。 应对公共卫生紧急情况 为了响应2009年H1N1的爆发，美国食品和药物管理局（FDA）向CDC发布了紧急使用授权（EUA），立即使用美国疾病控制和预防中心（CDC）设计的qRT-PCR方法检测分析2009年H1N1。CDC很快开发了2009 H1N1Panel，以检测和识别新型流感A（H1N1）病毒的病例，并且是个面向公共卫生和其他合格实验室进行分子诊断试验的FDA授权分销商。Biosearch Technologies通过提供H1N1检测Panel所需的探针和引物参与了对流感大流行的快速反应。 世界卫生组织（WHO）在网上公布了其流感A（H1N1）qRT-PCR的CDC方案，列出了来自LGC Biosearch的Black HoleQuencher®（BHQ®-1）染料作为所有其所列探针的猝灭剂。 The 2009 H1N1 (Novel Influenza A) ValuPanel™ Reagents* are part of LGC Biosearch Technologies’ ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. *For Research Use Only. Not for use in diagnostic procedures. 2009 H1N1 Signatures Licensed from the CDC** As a licensed manufacturer of oligonucleotides to resolve 2009 H1N1 signatures, LGC Biosearch Technologies is pleased to offer the same sequences in the form of ValuPanel Reagents. This panel consists of dual-labeled BHQ probes, a forward primer, and a reverse primer for use in real-time qPCR to discriminate H1N1-related viral strains. 2009 H1N1 ValuPanel Reagents contain probes and primers based on genetic signatures for the following strains: Influenza A Swine Influenza A Swine H1 Influenza A Human RNase P (Extraction Control) These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the 2009 H1N1 diagnostic test. **CDC does not endorse products or services. Responding to a Public Health Emergency In response to the outbreak of novel 2009 H1N1, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to the CDC for the immediate use of the Real-time RT-PCR Detection Assays for 2009 H1N1 designed by the US Centers for Disease Control and Prevention (CDC). The CDC readily developed the 2009 H1N1 Panel to detect and identify cases of the novel influenza A (H1N1) virus, and is the first FDA-authorized distributor of this molecular diagnostic test to public health and other qualified laboratories. Biosearch Technologies participated in the rapid response to the Flu pandemic by supplying the probes and primers necessary for the H1N1 detection panel. Available to the public online, the World Health Organization (WHO) posted the CDC protocol of realtime RTPCR for influenza A (H1N1) which lists the Black Hole Quencher® (BHQ®-1) dye from LGC Biosearch as the quencher for all listed probes.

2009年H1N1（新型流感A）ValuPanel™试剂*是LGC Biosearch Technologies的ValuPanel检测试剂系列的一部分。ValuPanel试剂由鉴定不同病原菌株的探针和引物组成。 *仅供研究使用，不用于诊断程序 2009年H1N1鉴定获CDC授权** 作为被授权的鉴定2009 H1N1的寡核苷酸制造商，LGC Biosearch 2009 H1N1检测Panel由用于qPCR的双标记BHQ探针、正向引物和反向引物组成，能够区分H1N1相关病毒株。2009 H1N1 ValuPanel试剂含有基于以下病毒株遗传鉴定的探针和引物： 流感A 猪流感A 猪H1流感 人类RNase P（提取对照） 这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物均采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 ** CDC不认可产品或服务。 应对公共卫生紧急情况 为了响应2009年H1N1的爆发，美国食品和药物管理局（FDA）向CDC发布了紧急使用授权（EUA），立即使用美国疾病控制和预防中心（CDC）设计的qRT-PCR方法检测分析2009年H1N1。CDC很快开发了2009 H1N1Panel，以检测和识别新型流感A（H1N1）病毒的病例，并且是个面向公共卫生和其他合格实验室进行分子诊断试验的FDA授权分销商。Biosearch Technologies通过提供H1N1检测Panel所需的探针和引物参与了对流感大流行的快速反应。 世界卫生组织（WHO）在网上公布了其流感A（H1N1）qRT-PCR的CDC方案，列出了来自LGC Biosearch的Black HoleQuencher®（BHQ®-1）染料作为所有其所列探针的猝灭剂。 The 2009 H1N1 (Novel Influenza A) ValuPanel™ Reagents* are part of LGC Biosearch Technologies’ ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. *For Research Use Only. Not for use in diagnostic procedures. 2009 H1N1 Signatures Licensed from the CDC** As a licensed manufacturer of oligonucleotides to resolve 2009 H1N1 signatures, LGC Biosearch Technologies is pleased to offer the same sequences in the form of ValuPanel Reagents. This panel consists of dual-labeled BHQ probes, a forward primer, and a reverse primer for use in real-time qPCR to discriminate H1N1-related viral strains. 2009 H1N1 ValuPanel Reagents contain probes and primers based on genetic signatures for the following strains: Influenza A Swine Influenza A Swine H1 Influenza A Human RNase P (Extraction Control) These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the 2009 H1N1 diagnostic test. **CDC does not endorse products or services. Responding to a Public Health Emergency In response to the outbreak of novel 2009 H1N1, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to the CDC for the immediate use of the Real-time RT-PCR Detection Assays for 2009 H1N1 designed by the US Centers for Disease Control and Prevention (CDC). The CDC readily developed the 2009 H1N1 Panel to detect and identify cases of the novel influenza A (H1N1) virus, and is the first FDA-authorized distributor of this molecular diagnostic test to public health and other qualified laboratories. Biosearch Technologies participated in the rapid response to the Flu pandemic by supplying the probes and primers necessary for the H1N1 detection panel. Available to the public online, the World Health Organization (WHO) posted the CDC protocol of realtime RTPCR for influenza A (H1N1) which lists the Black Hole Quencher® (BHQ®-1) dye from LGC Biosearch as the quencher for all listed probes.

2009年H1N1（新型流感A）ValuPanel™试剂*是LGC Biosearch Technologies的ValuPanel检测试剂系列的一部分。ValuPanel试剂由鉴定不同病原菌株的探针和引物组成。 *仅供研究使用，不用于诊断程序 2009年H1N1鉴定获CDC授权** 作为被授权的鉴定2009 H1N1的寡核苷酸制造商，LGC Biosearch 2009 H1N1检测Panel由用于qPCR的双标记BHQ探针、正向引物和反向引物组成，能够区分H1N1相关病毒株。2009 H1N1 ValuPanel试剂含有基于以下病毒株遗传鉴定的探针和引物： 流感A 猪流感A 猪H1流感 人类RNase P（提取对照） 这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物均采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 ** CDC不认可产品或服务。 应对公共卫生紧急情况 为了响应2009年H1N1的爆发，美国食品和药物管理局（FDA）向CDC发布了紧急使用授权（EUA），立即使用美国疾病控制和预防中心（CDC）设计的qRT-PCR方法检测分析2009年H1N1。CDC很快开发了2009 H1N1Panel，以检测和识别新型流感A（H1N1）病毒的病例，并且是个面向公共卫生和其他合格实验室进行分子诊断试验的FDA授权分销商。Biosearch Technologies通过提供H1N1检测Panel所需的探针和引物参与了对流感大流行的快速反应。 世界卫生组织（WHO）在网上公布了其流感A（H1N1）qRT-PCR的CDC方案，列出了来自LGC Biosearch的Black HoleQuencher®（BHQ®-1）染料作为所有其所列探针的猝灭剂。 The 2009 H1N1 (Novel Influenza A) ValuPanel™ Reagents* are part of LGC Biosearch Technologies’ ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. *For Research Use Only. Not for use in diagnostic procedures. 2009 H1N1 Signatures Licensed from the CDC** As a licensed manufacturer of oligonucleotides to resolve 2009 H1N1 signatures, LGC Biosearch Technologies is pleased to offer the same sequences in the form of ValuPanel Reagents. This panel consists of dual-labeled BHQ probes, a forward primer, and a reverse primer for use in real-time qPCR to discriminate H1N1-related viral strains. 2009 H1N1 ValuPanel Reagents contain probes and primers based on genetic signatures for the following strains: Influenza A Swine Influenza A Swine H1 Influenza A Human RNase P (Extraction Control) These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the 2009 H1N1 diagnostic test. **CDC does not endorse products or services. Responding to a Public Health Emergency In response to the outbreak of novel 2009 H1N1, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to the CDC for the immediate use of the Real-time RT-PCR Detection Assays for 2009 H1N1 designed by the US Centers for Disease Control and Prevention (CDC). The CDC readily developed the 2009 H1N1 Panel to detect and identify cases of the novel influenza A (H1N1) virus, and is the first FDA-authorized distributor of this molecular diagnostic test to public health and other qualified laboratories. Biosearch Technologies participated in the rapid response to the Flu pandemic by supplying the probes and primers necessary for the H1N1 detection panel. Available to the public online, the World Health Organization (WHO) posted the CDC protocol of realtime RTPCR for influenza A (H1N1) which lists the Black Hole Quencher® (BHQ®-1) dye from LGC Biosearch as the quencher for all listed probes.

ValuPanel™试剂*由RT-qPCR的探针和引物组成，用于不同病原菌株的遗传鉴定。 *仅供研究使用。不用于诊断程序。 获CDC授权的甲型流感病毒亚型鉴定** 作为被授权的鉴定甲型流感亚型（季节性流感）的寡核苷酸制造商，LGC Biosearch提供所有主要流感病毒株的检测鉴定试剂，这些试剂Panel由用于qPCR的双标记BHQ探针、正向引物和反向引物组成，能够区分不同流感亚型的序列。甲型流感ValuPanel试剂含有基于以下菌株的遗传鉴定的探针和引物： 甲型（A）流感和乙型（B）流感 甲型流感亚型H1、H3和H5 人类RNase P（提取对照） 这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物均采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 ** CDC不认可产品或服务。 ValuPanel™ Reagents are composed of probes and primers for RT-qPCR to resolve the genetic signatures of different pathogen strains. LGC Biosearch Technologies is pleased to introduce Influenza A subtyping to the catalog of ValuPanel Reagents*. *For Research Use Only. Not for use in diagnostic procedures. Influenza A Subtyping Signatures Licensed from the CDC** As a licensed manufacturer of oligonucleotides to resolve influenza A subtypes (seasonal flu), LGC Biosearch is pleased to provide these important reagents for the detection of all major strains of influenza. This panel consists of dual-labeled BHQ® probes, a forward primer, and a reverse primer for use in real-time qPCR, to discriminate the sequences of influenza subtypes. Influenza A ValuPanel Reagents contain probes and primers based on genetic signatures for the following strains: Influenza A and Influenza B Influenza A subtypes H1, H3, and H5 Human RNase P (Extraction Control) These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the Influenza A subtyping panel. **CDC does not endorse products or services.

禽甲型流感（H7N9）ValuPanel™试剂*是ValuPanel系列检测试剂的一部分。ValuPanel试剂由检测不同病原菌株遗传信号的探针和引物组成，能够区分在2013年流行的导致禽流感并能够感染人类的禽流感H7N9病毒。这种病毒不同于早期的禽流感病毒株H5N1和仅在鸟类中发现的禽流感病毒株。 该Panel由双标记BHQ探针组成，用于qPCR实验中，以区分H7N9病毒株。这个新的ValuPanel包含以下几种基因的探针和引物： 通用甲型流感病毒 甲型流感病毒亚型H7和N9 人类RNase P（提取对照） H7和N9亚型的寡核苷酸序列由世界卫生组织（WHO）在中国国家流感中心（CNIC）的流感备案和研究合作中心设计。通用甲型流感和RNase P序列由美国疾病控制和预防中心（CDC**）设计并获得许可。N9亚型的正向和反向引物序列用的是2013年4月15日的修订方案中列出的CNIC-WHO的优化序列。所有探针用FAM和Black Hole Quencher（BHQ）染料标记，且采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 *仅供研究使用。不用于诊断程序。 ** CDC不认可产品或服务。 Avian Influenza A (H7N9) ValuPanel™ Reagents* are now part of the ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These signatures discriminate the H7N9 virus that causes avian (bird) flu, and capable of infecting humans when circulating in 2013. This virus differs from earlier avian flu strains including H5N1, and others found only in birds. This panel consists of dual-labeled BHQ® probes for use in real-time qPCR to discriminate H7N9 viral strains. This new ValuPanel contains probes and primers based on genetic signatures for the following: Universal Influenza A Influenza A subtypes H7 and N9 Human RNase P (Extraction Control) Oligonucleotide sequences for the H7 and N9 subtypes were designed by the World Health Organization (WHO) Collaborating Center for Reference and Research on Influenza at the Chinese National Influenza Center (CNIC) in Beijing, China. Universal Influenza A and RNase P sequences were designed by and licensed from the US Centers for Disease Control and Prevention (CDC**). Sequences for the forward and reverse primers for the N9 subtype correspond to the CNIC-WHO’s optimized sequences as listed in the revised protocol dated April 15th, 2013. All probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes, and are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes included in the Avian Influenza A (H7N9) panel. *For Research Use Only. Not for use in diagnostic procedures. **CDC does not endorse products or services.

禽甲型流感（H7N9）ValuPanel™试剂*是ValuPanel系列检测试剂的一部分。ValuPanel试剂由检测不同病原菌株遗传信号的探针和引物组成，能够区分在2013年流行的导致禽流感并能够感染人类的禽流感H7N9病毒。这种病毒不同于早期的禽流感病毒株H5N1和仅在鸟类中发现的禽流感病毒株。 该Panel由双标记BHQ探针组成，用于qPCR实验中，以区分H7N9病毒株。这个新的ValuPanel包含以下几种基因的探针和引物： 通用甲型流感病毒 甲型流感病毒亚型H7和N9 人类RNase P（提取对照） H7和N9亚型的寡核苷酸序列由世界卫生组织（WHO）在中国国家流感中心（CNIC）的流感备案和研究合作中心设计。通用甲型流感和RNase P序列由美国疾病控制和预防中心（CDC**）设计并获得许可。N9亚型的正向和反向引物序列用的是2013年4月15日的修订方案中列出的CNIC-WHO的优化序列。所有探针用FAM和Black Hole Quencher（BHQ）染料标记，且采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 *仅供研究使用。不用于诊断程序。 ** CDC不认可产品或服务。 Avian Influenza A (H7N9) ValuPanel™ Reagents* are now part of the ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These signatures discriminate the H7N9 virus that causes avian (bird) flu, and capable of infecting humans when circulating in 2013. This virus differs from earlier avian flu strains including H5N1, and others found only in birds. This panel consists of dual-labeled BHQ® probes for use in real-time qPCR to discriminate H7N9 viral strains. This new ValuPanel contains probes and primers based on genetic signatures for the following: Universal Influenza A Influenza A subtypes H7 and N9 Human RNase P (Extraction Control) Oligonucleotide sequences for the H7 and N9 subtypes were designed by the World Health Organization (WHO) Collaborating Center for Reference and Research on Influenza at the Chinese National Influenza Center (CNIC) in Beijing, China. Universal Influenza A and RNase P sequences were designed by and licensed from the US Centers for Disease Control and Prevention (CDC**). Sequences for the forward and reverse primers for the N9 subtype correspond to the CNIC-WHO’s optimized sequences as listed in the revised protocol dated April 15th, 2013. All probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes, and are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes included in the Avian Influenza A (H7N9) panel. *For Research Use Only. Not for use in diagnostic procedures. **CDC does not endorse products or services.

禽甲型流感（H7N9）ValuPanel™试剂*是ValuPanel系列检测试剂的一部分。ValuPanel试剂由检测不同病原菌株遗传信号的探针和引物组成，能够区分在2013年流行的导致禽流感并能够感染人类的禽流感H7N9病毒。这种病毒不同于早期的禽流感病毒株H5N1和仅在鸟类中发现的禽流感病毒株。 该Panel由双标记BHQ探针组成，用于qPCR实验中，以区分H7N9病毒株。这个新的ValuPanel包含以下几种基因的探针和引物： 通用甲型流感病毒 甲型流感病毒亚型H7和N9 人类RNase P（提取对照） H7和N9亚型的寡核苷酸序列由世界卫生组织（WHO）在中国国家流感中心（CNIC）的流感备案和研究合作中心设计。通用甲型流感和RNase P序列由美国疾病控制和预防中心（CDC**）设计并获得许可。N9亚型的正向和反向引物序列用的是2013年4月15日的修订方案中列出的CNIC-WHO的优化序列。所有探针用FAM和Black Hole Quencher（BHQ）染料标记，且采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 *仅供研究使用。不用于诊断程序。 ** CDC不认可产品或服务。 Avian Influenza A (H7N9) ValuPanel™ Reagents* are now part of the ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These signatures discriminate the H7N9 virus that causes avian (bird) flu, and capable of infecting humans when circulating in 2013. This virus differs from earlier avian flu strains including H5N1, and others found only in birds. This panel consists of dual-labeled BHQ® probes for use in real-time qPCR to discriminate H7N9 viral strains. This new ValuPanel contains probes and primers based on genetic signatures for the following: Universal Influenza A Influenza A subtypes H7 and N9 Human RNase P (Extraction Control) Oligonucleotide sequences for the H7 and N9 subtypes were designed by the World Health Organization (WHO) Collaborating Center for Reference and Research on Influenza at the Chinese National Influenza Center (CNIC) in Beijing, China. Universal Influenza A and RNase P sequences were designed by and licensed from the US Centers for Disease Control and Prevention (CDC**). Sequences for the forward and reverse primers for the N9 subtype correspond to the CNIC-WHO’s optimized sequences as listed in the revised protocol dated April 15th, 2013. All probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes, and are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes included in the Avian Influenza A (H7N9) panel. *For Research Use Only. Not for use in diagnostic procedures. **CDC does not endorse products or services.

禽甲型流感（H7N9）ValuPanel™试剂*是ValuPanel系列检测试剂的一部分。ValuPanel试剂由检测不同病原菌株遗传信号的探针和引物组成，能够区分在2013年流行的导致禽流感并能够感染人类的禽流感H7N9病毒。这种病毒不同于早期的禽流感病毒株H5N1和仅在鸟类中发现的禽流感病毒株。 该Panel由双标记BHQ探针组成，用于qPCR实验中，以区分H7N9病毒株。这个新的ValuPanel包含以下几种基因的探针和引物： 通用甲型流感病毒 甲型流感病毒亚型H7和N9 人类RNase P（提取对照） H7和N9亚型的寡核苷酸序列由世界卫生组织（WHO）在中国国家流感中心（CNIC）的流感备案和研究合作中心设计。通用甲型流感和RNase P序列由美国疾病控制和预防中心（CDC**）设计并获得许可。N9亚型的正向和反向引物序列用的是2013年4月15日的修订方案中列出的CNIC-WHO的优化序列。所有探针用FAM和Black Hole Quencher（BHQ）染料标记，且采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 *仅供研究使用。不用于诊断程序。 ** CDC不认可产品或服务。 Avian Influenza A (H7N9) ValuPanel™ Reagents* are now part of the ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These signatures discriminate the H7N9 virus that causes avian (bird) flu, and capable of infecting humans when circulating in 2013. This virus differs from earlier avian flu strains including H5N1, and others found only in birds. This panel consists of dual-labeled BHQ® probes for use in real-time qPCR to discriminate H7N9 viral strains. This new ValuPanel contains probes and primers based on genetic signatures for the following: Universal Influenza A Influenza A subtypes H7 and N9 Human RNase P (Extraction Control) Oligonucleotide sequences for the H7 and N9 subtypes were designed by the World Health Organization (WHO) Collaborating Center for Reference and Research on Influenza at the Chinese National Influenza Center (CNIC) in Beijing, China. Universal Influenza A and RNase P sequences were designed by and licensed from the US Centers for Disease Control and Prevention (CDC**). Sequences for the forward and reverse primers for the N9 subtype correspond to the CNIC-WHO’s optimized sequences as listed in the revised protocol dated April 15th, 2013. All probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes, and are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes included in the Avian Influenza A (H7N9) panel. *For Research Use Only. Not for use in diagnostic procedures. **CDC does not endorse products or services.

禽甲型流感（H7N9）ValuPanel™试剂*是ValuPanel系列检测试剂的一部分。ValuPanel试剂由检测不同病原菌株遗传信号的探针和引物组成，能够区分在2013年流行的导致禽流感并能够感染人类的禽流感H7N9病毒。这种病毒不同于早期的禽流感病毒株H5N1和仅在鸟类中发现的禽流感病毒株。 该Panel由双标记BHQ探针组成，用于qPCR实验中，以区分H7N9病毒株。这个新的ValuPanel包含以下几种基因的探针和引物： 通用甲型流感病毒 甲型流感病毒亚型H7和N9 人类RNase P（提取对照） H7和N9亚型的寡核苷酸序列由世界卫生组织（WHO）在中国国家流感中心（CNIC）的流感备案和研究合作中心设计。通用甲型流感和RNase P序列由美国疾病控制和预防中心（CDC**）设计并获得许可。N9亚型的正向和反向引物序列用的是2013年4月15日的修订方案中列出的CNIC-WHO的优化序列。所有探针用FAM和Black Hole Quencher（BHQ）染料标记，且采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 *仅供研究使用。不用于诊断程序。 ** CDC不认可产品或服务。 Avian Influenza A (H7N9) ValuPanel™ Reagents* are now part of the ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These signatures discriminate the H7N9 virus that causes avian (bird) flu, and capable of infecting humans when circulating in 2013. This virus differs from earlier avian flu strains including H5N1, and others found only in birds. This panel consists of dual-labeled BHQ® probes for use in real-time qPCR to discriminate H7N9 viral strains. This new ValuPanel contains probes and primers based on genetic signatures for the following: Universal Influenza A Influenza A subtypes H7 and N9 Human RNase P (Extraction Control) Oligonucleotide sequences for the H7 and N9 subtypes were designed by the World Health Organization (WHO) Collaborating Center for Reference and Research on Influenza at the Chinese National Influenza Center (CNIC) in Beijing, China. Universal Influenza A and RNase P sequences were designed by and licensed from the US Centers for Disease Control and Prevention (CDC**). Sequences for the forward and reverse primers for the N9 subtype correspond to the CNIC-WHO’s optimized sequences as listed in the revised protocol dated April 15th, 2013. All probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes, and are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes included in the Avian Influenza A (H7N9) panel. *For Research Use Only. Not for use in diagnostic procedures. **CDC does not endorse products or services.

禽甲型流感（H7N9）ValuPanel™试剂*是ValuPanel系列检测试剂的一部分。ValuPanel试剂由检测不同病原菌株遗传信号的探针和引物组成，能够区分在2013年流行的导致禽流感并能够感染人类的禽流感H7N9病毒。这种病毒不同于早期的禽流感病毒株H5N1和仅在鸟类中发现的禽流感病毒株。 该Panel由双标记BHQ探针组成，用于qPCR实验中，以区分H7N9病毒株。这个新的ValuPanel包含以下几种基因的探针和引物： 通用甲型流感病毒 甲型流感病毒亚型H7和N9 人类RNase P（提取对照） H7和N9亚型的寡核苷酸序列由世界卫生组织（WHO）在中国国家流感中心（CNIC）的流感备案和研究合作中心设计。通用甲型流感和RNase P序列由美国疾病控制和预防中心（CDC**）设计并获得许可。N9亚型的正向和反向引物序列用的是2013年4月15日的修订方案中列出的CNIC-WHO的优化序列。所有探针用FAM和Black Hole Quencher（BHQ）染料标记，且采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 *仅供研究使用。不用于诊断程序。 ** CDC不认可产品或服务。 Avian Influenza A (H7N9) ValuPanel™ Reagents* are now part of the ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These signatures discriminate the H7N9 virus that causes avian (bird) flu, and capable of infecting humans when circulating in 2013. This virus differs from earlier avian flu strains including H5N1, and others found only in birds. This panel consists of dual-labeled BHQ® probes for use in real-time qPCR to discriminate H7N9 viral strains. This new ValuPanel contains probes and primers based on genetic signatures for the following: Universal Influenza A Influenza A subtypes H7 and N9 Human RNase P (Extraction Control) Oligonucleotide sequences for the H7 and N9 subtypes were designed by the World Health Organization (WHO) Collaborating Center for Reference and Research on Influenza at the Chinese National Influenza Center (CNIC) in Beijing, China. Universal Influenza A and RNase P sequences were designed by and licensed from the US Centers for Disease Control and Prevention (CDC**). Sequences for the forward and reverse primers for the N9 subtype correspond to the CNIC-WHO’s optimized sequences as listed in the revised protocol dated April 15th, 2013. All probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes, and are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes included in the Avian Influenza A (H7N9) panel. *For Research Use Only. Not for use in diagnostic procedures. **CDC does not endorse products or services.

PDM 2009 H1N1（新型流感A）ValuPanel TM试剂*是LGC Biosearch Technologies的ValuPanel系列检测试剂的一部分。 ValuPanel试剂由鉴定不同病原菌株的探针和引物组成。这些新的PDM检测试剂被证明具有比原始2009年H1N1探针和引物更好的性能：这个更新的Panel对2009 H1N1具有更强的特异性和灵敏度。 *仅供研究使用。不用于诊断程序。 PDM 2009 H1N1鉴定获美国CDC许可** LGC Biosearch Technologies是一家授权的寡核苷酸制造商，其制造的寡核苷酸可用于2009 H1N1流行病的遗传鉴定。该Panel由双标记BHQ探针、正向引物和反向引物组成，用在实时定量PCR中以区分新型流感A H1N1与其他病毒株。PDM 2009 H1N1 ValuPanel试剂包含基于以下遗传鉴定的探针和引物： 通用流感A PDM流感A（猪流感特异性） PDM H1（猪流感特异性） 人类RNase P（提取对照） 这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物经HPLC纯化。 LGC Biosearch是BHQ染料的发明者，是目前在标记探针中使用真正黑暗淬灭剂BHQ的制造商。 ** CDC不认可产品或服务 PDM 2009 H1N1与原始2009年H1N1 ValuPanel试剂有何区别？ 改进的特异性 - 新的探针和引物靶向在原始小组中解析的相同基因的更保守区域。因此，它们适用于检测在国际上出现的新型甲型流感H1N1的多种分离株，同时区分其他流感类型和菌株。 改进的灵敏度 - PDM 2009 H1N1 ValuPanel试剂被开发用于检测较少的新型流感病毒A的拷贝。 The PDM 2009 H1N1 (Novel Influenza A) ValuPanel™ Reagents* are part of LGC Biosearch Technologies’ ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These new PDM signatures demonstrate improved performance over the original 2009 H1N1 probes and primers: this updated panel targets the 2009 H1N1 with more specificity and sensitivity. *For Research Use Only. Not for use in diagnostic procedures. PDM 2009 H1N1 Signatures Licensed from the CDC** LGC Biosearch Technologies is a licensed manufacturer of oligonucleotides to resolve the genetic signatures of the 2009 H1N1 pandemic. This panel consists of dual-labeled BHQ® probes, a forward primer, and a reverse primer for use in real-time PCR to discriminate novel influenza A H1N1 from other viral strains. PDM 2009 H1N1 ValuPanel Reagents contain probes and primers based on the following genetic signatures: Universal Influenza A PDM Influenza A (Swine Flu Specific) PDM H1 (Swine Flu Specific) Human RNase P (Extraction Control) These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the 2009 H1N1 diagnostic test. **CDC does not endorse products or services How is PDM 2009 H1N1 Different than the Original 2009 H1N1 ValuPanel Reagents? Improved Specificity – the new probes and primers target more conserved regions of the same genes that were resolved in the original panel. They are therefore appropriate for detection of diverse isolates of Novel Influenza A H1N1 that emerged internationally, while discriminating against other flu types and strains. Improved Sensitivity – PDM 2009 H1N1 ValuPanel Reagents were developed for detection of fewer copies of Novel Influenza A.

PDM 2009 H1N1（新型流感A）ValuPanel TM试剂*是LGC Biosearch Technologies的ValuPanel系列检测试剂的一部分。 ValuPanel试剂由鉴定不同病原菌株的探针和引物组成。这些新的PDM检测试剂被证明具有比原始2009年H1N1探针和引物更好的性能：这个更新的Panel对2009 H1N1具有更强的特异性和灵敏度。 *仅供研究使用。不用于诊断程序。 PDM 2009 H1N1鉴定获美国CDC许可** LGC Biosearch Technologies是一家授权的寡核苷酸制造商，其制造的寡核苷酸可用于2009 H1N1流行病的遗传鉴定。该Panel由双标记BHQ探针、正向引物和反向引物组成，用在实时定量PCR中以区分新型流感A H1N1与其他病毒株。PDM 2009 H1N1 ValuPanel试剂包含基于以下遗传鉴定的探针和引物： 通用流感A PDM流感A（猪流感特异性） PDM H1（猪流感特异性） 人类RNase P（提取对照） 这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物经HPLC纯化。 LGC Biosearch是BHQ染料的发明者，是目前在标记探针中使用真正黑暗淬灭剂BHQ的制造商。 ** CDC不认可产品或服务 PDM 2009 H1N1与原始2009年H1N1 ValuPanel试剂有何区别？ 改进的特异性 - 新的探针和引物靶向在原始小组中解析的相同基因的更保守区域。因此，它们适用于检测在国际上出现的新型甲型流感H1N1的多种分离株，同时区分其他流感类型和菌株。 改进的灵敏度 - PDM 2009 H1N1 ValuPanel试剂被开发用于检测较少的新型流感病毒A的拷贝。 The PDM 2009 H1N1 (Novel Influenza A) ValuPanel™ Reagents* are part of LGC Biosearch Technologies’ ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These new PDM signatures demonstrate improved performance over the original 2009 H1N1 probes and primers: this updated panel targets the 2009 H1N1 with more specificity and sensitivity. *For Research Use Only. Not for use in diagnostic procedures. PDM 2009 H1N1 Signatures Licensed from the CDC** LGC Biosearch Technologies is a licensed manufacturer of oligonucleotides to resolve the genetic signatures of the 2009 H1N1 pandemic. This panel consists of dual-labeled BHQ® probes, a forward primer, and a reverse primer for use in real-time PCR to discriminate novel influenza A H1N1 from other viral strains. PDM 2009 H1N1 ValuPanel Reagents contain probes and primers based on the following genetic signatures: Universal Influenza A PDM Influenza A (Swine Flu Specific) PDM H1 (Swine Flu Specific) Human RNase P (Extraction Control) These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the 2009 H1N1 diagnostic test. **CDC does not endorse products or services How is PDM 2009 H1N1 Different than the Original 2009 H1N1 ValuPanel Reagents? Improved Specificity – the new probes and primers target more conserved regions of the same genes that were resolved in the original panel. They are therefore appropriate for detection of diverse isolates of Novel Influenza A H1N1 that emerged internationally, while discriminating against other flu types and strains. Improved Sensitivity – PDM 2009 H1N1 ValuPanel Reagents were developed for detection of fewer copies of Novel Influenza A.

PDM 2009 H1N1（新型流感A）ValuPanel TM试剂*是LGC Biosearch Technologies的ValuPanel系列检测试剂的一部分。 ValuPanel试剂由鉴定不同病原菌株的探针和引物组成。这些新的PDM检测试剂被证明具有比原始2009年H1N1探针和引物更好的性能：这个更新的Panel对2009 H1N1具有更强的特异性和灵敏度。 *仅供研究使用。不用于诊断程序。 PDM 2009 H1N1鉴定获美国CDC许可** LGC Biosearch Technologies是一家授权的寡核苷酸制造商，其制造的寡核苷酸可用于2009 H1N1流行病的遗传鉴定。该Panel由双标记BHQ探针、正向引物和反向引物组成，用在实时定量PCR中以区分新型流感A H1N1与其他病毒株。PDM 2009 H1N1 ValuPanel试剂包含基于以下遗传鉴定的探针和引物： 通用流感A PDM流感A（猪流感特异性） PDM H1（猪流感特异性） 人类RNase P（提取对照） 这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物经HPLC纯化。 LGC Biosearch是BHQ染料的发明者，是目前在标记探针中使用真正黑暗淬灭剂BHQ的制造商。 ** CDC不认可产品或服务 PDM 2009 H1N1与原始2009年H1N1 ValuPanel试剂有何区别？ 改进的特异性 - 新的探针和引物靶向在原始小组中解析的相同基因的更保守区域。因此，它们适用于检测在国际上出现的新型甲型流感H1N1的多种分离株，同时区分其他流感类型和菌株。 改进的灵敏度 - PDM 2009 H1N1 ValuPanel试剂被开发用于检测较少的新型流感病毒A的拷贝。 The PDM 2009 H1N1 (Novel Influenza A) ValuPanel™ Reagents* are part of LGC Biosearch Technologies’ ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These new PDM signatures demonstrate improved performance over the original 2009 H1N1 probes and primers: this updated panel targets the 2009 H1N1 with more specificity and sensitivity. *For Research Use Only. Not for use in diagnostic procedures. PDM 2009 H1N1 Signatures Licensed from the CDC** LGC Biosearch Technologies is a licensed manufacturer of oligonucleotides to resolve the genetic signatures of the 2009 H1N1 pandemic. This panel consists of dual-labeled BHQ® probes, a forward primer, and a reverse primer for use in real-time PCR to discriminate novel influenza A H1N1 from other viral strains. PDM 2009 H1N1 ValuPanel Reagents contain probes and primers based on the following genetic signatures: Universal Influenza A PDM Influenza A (Swine Flu Specific) PDM H1 (Swine Flu Specific) Human RNase P (Extraction Control) These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the 2009 H1N1 diagnostic test. **CDC does not endorse products or services How is PDM 2009 H1N1 Different than the Original 2009 H1N1 ValuPanel Reagents? Improved Specificity – the new probes and primers target more conserved regions of the same genes that were resolved in the original panel. They are therefore appropriate for detection of diverse isolates of Novel Influenza A H1N1 that emerged internationally, while discriminating against other flu types and strains. Improved Sensitivity – PDM 2009 H1N1 ValuPanel Reagents were developed for detection of fewer copies of Novel Influenza A.

PDM 2009 H1N1（新型流感A）ValuPanel TM试剂*是LGC Biosearch Technologies的ValuPanel系列检测试剂的一部分。 ValuPanel试剂由鉴定不同病原菌株的探针和引物组成。这些新的PDM检测试剂被证明具有比原始2009年H1N1探针和引物更好的性能：这个更新的Panel对2009 H1N1具有更强的特异性和灵敏度。 *仅供研究使用。不用于诊断程序。 PDM 2009 H1N1鉴定获美国CDC许可** LGC Biosearch Technologies是一家授权的寡核苷酸制造商，其制造的寡核苷酸可用于2009 H1N1流行病的遗传鉴定。该Panel由双标记BHQ探针、正向引物和反向引物组成，用在实时定量PCR中以区分新型流感A H1N1与其他病毒株。PDM 2009 H1N1 ValuPanel试剂包含基于以下遗传鉴定的探针和引物： 通用流感A PDM流感A（猪流感特异性） PDM H1（猪流感特异性） 人类RNase P（提取对照） 这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物经HPLC纯化。 LGC Biosearch是BHQ染料的发明者，是目前在标记探针中使用真正黑暗淬灭剂BHQ的制造商。 ** CDC不认可产品或服务 PDM 2009 H1N1与原始2009年H1N1 ValuPanel试剂有何区别？ 改进的特异性 - 新的探针和引物靶向在原始小组中解析的相同基因的更保守区域。因此，它们适用于检测在国际上出现的新型甲型流感H1N1的多种分离株，同时区分其他流感类型和菌株。 改进的灵敏度 - PDM 2009 H1N1 ValuPanel试剂被开发用于检测较少的新型流感病毒A的拷贝。 The PDM 2009 H1N1 (Novel Influenza A) ValuPanel™ Reagents* are part of LGC Biosearch Technologies’ ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These new PDM signatures demonstrate improved performance over the original 2009 H1N1 probes and primers: this updated panel targets the 2009 H1N1 with more specificity and sensitivity. *For Research Use Only. Not for use in diagnostic procedures. PDM 2009 H1N1 Signatures Licensed from the CDC** LGC Biosearch Technologies is a licensed manufacturer of oligonucleotides to resolve the genetic signatures of the 2009 H1N1 pandemic. This panel consists of dual-labeled BHQ® probes, a forward primer, and a reverse primer for use in real-time PCR to discriminate novel influenza A H1N1 from other viral strains. PDM 2009 H1N1 ValuPanel Reagents contain probes and primers based on the following genetic signatures: Universal Influenza A PDM Influenza A (Swine Flu Specific) PDM H1 (Swine Flu Specific) Human RNase P (Extraction Control) These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the 2009 H1N1 diagnostic test. **CDC does not endorse products or services How is PDM 2009 H1N1 Different than the Original 2009 H1N1 ValuPanel Reagents? Improved Specificity – the new probes and primers target more conserved regions of the same genes that were resolved in the original panel. They are therefore appropriate for detection of diverse isolates of Novel Influenza A H1N1 that emerged internationally, while discriminating against other flu types and strains. Improved Sensitivity – PDM 2009 H1N1 ValuPanel Reagents were developed for detection of fewer copies of Novel Influenza A.

PDM 2009 H1N1（新型流感A）ValuPanel TM试剂*是LGC Biosearch Technologies的ValuPanel系列检测试剂的一部分。 ValuPanel试剂由鉴定不同病原菌株的探针和引物组成。这些新的PDM检测试剂被证明具有比原始2009年H1N1探针和引物更好的性能：这个更新的Panel对2009 H1N1具有更强的特异性和灵敏度。 *仅供研究使用。不用于诊断程序。 PDM 2009 H1N1鉴定获美国CDC许可** LGC Biosearch Technologies是一家授权的寡核苷酸制造商，其制造的寡核苷酸可用于2009 H1N1流行病的遗传鉴定。该Panel由双标记BHQ探针、正向引物和反向引物组成，用在实时定量PCR中以区分新型流感A H1N1与其他病毒株。PDM 2009 H1N1 ValuPanel试剂包含基于以下遗传鉴定的探针和引物： 通用流感A PDM流感A（猪流感特异性） PDM H1（猪流感特异性） 人类RNase P（提取对照） 这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物经HPLC纯化。 LGC Biosearch是BHQ染料的发明者，是目前在标记探针中使用真正黑暗淬灭剂BHQ的制造商。 ** CDC不认可产品或服务 PDM 2009 H1N1与原始2009年H1N1 ValuPanel试剂有何区别？ 改进的特异性 - 新的探针和引物靶向在原始小组中解析的相同基因的更保守区域。因此，它们适用于检测在国际上出现的新型甲型流感H1N1的多种分离株，同时区分其他流感类型和菌株。 改进的灵敏度 - PDM 2009 H1N1 ValuPanel试剂被开发用于检测较少的新型流感病毒A的拷贝。 The PDM 2009 H1N1 (Novel Influenza A) ValuPanel™ Reagents* are part of LGC Biosearch Technologies’ ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These new PDM signatures demonstrate improved performance over the original 2009 H1N1 probes and primers: this updated panel targets the 2009 H1N1 with more specificity and sensitivity. *For Research Use Only. Not for use in diagnostic procedures. PDM 2009 H1N1 Signatures Licensed from the CDC** LGC Biosearch Technologies is a licensed manufacturer of oligonucleotides to resolve the genetic signatures of the 2009 H1N1 pandemic. This panel consists of dual-labeled BHQ® probes, a forward primer, and a reverse primer for use in real-time PCR to discriminate novel influenza A H1N1 from other viral strains. PDM 2009 H1N1 ValuPanel Reagents contain probes and primers based on the following genetic signatures: Universal Influenza A PDM Influenza A (Swine Flu Specific) PDM H1 (Swine Flu Specific) Human RNase P (Extraction Control) These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the 2009 H1N1 diagnostic test. **CDC does not endorse products or services How is PDM 2009 H1N1 Different than the Original 2009 H1N1 ValuPanel Reagents? Improved Specificity – the new probes and primers target more conserved regions of the same genes that were resolved in the original panel. They are therefore appropriate for detection of diverse isolates of Novel Influenza A H1N1 that emerged internationally, while discriminating against other flu types and strains. Improved Sensitivity – PDM 2009 H1N1 ValuPanel Reagents were developed for detection of fewer copies of Novel Influenza A.

PDM 2009 H1N1（新型流感A）ValuPanel TM试剂*是LGC Biosearch Technologies的ValuPanel系列检测试剂的一部分。 ValuPanel试剂由鉴定不同病原菌株的探针和引物组成。这些新的PDM检测试剂被证明具有比原始2009年H1N1探针和引物更好的性能：这个更新的Panel对2009 H1N1具有更强的特异性和灵敏度。 *仅供研究使用。不用于诊断程序。 PDM 2009 H1N1鉴定获美国CDC许可** LGC Biosearch Technologies是一家授权的寡核苷酸制造商，其制造的寡核苷酸可用于2009 H1N1流行病的遗传鉴定。该Panel由双标记BHQ探针、正向引物和反向引物组成，用在实时定量PCR中以区分新型流感A H1N1与其他病毒株。PDM 2009 H1N1 ValuPanel试剂包含基于以下遗传鉴定的探针和引物： 通用流感A PDM流感A（猪流感特异性） PDM H1（猪流感特异性） 人类RNase P（提取对照） 这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物经HPLC纯化。 LGC Biosearch是BHQ染料的发明者，是目前在标记探针中使用真正黑暗淬灭剂BHQ的制造商。 ** CDC不认可产品或服务 PDM 2009 H1N1与原始2009年H1N1 ValuPanel试剂有何区别？ 改进的特异性 - 新的探针和引物靶向在原始小组中解析的相同基因的更保守区域。因此，它们适用于检测在国际上出现的新型甲型流感H1N1的多种分离株，同时区分其他流感类型和菌株。 改进的灵敏度 - PDM 2009 H1N1 ValuPanel试剂被开发用于检测较少的新型流感病毒A的拷贝。 The PDM 2009 H1N1 (Novel Influenza A) ValuPanel™ Reagents* are part of LGC Biosearch Technologies’ ValuPanel line of detection reagents. ValuPanel Reagents are composed of probes and primers that resolve genetic signatures of different pathogen strains. These new PDM signatures demonstrate improved performance over the original 2009 H1N1 probes and primers: this updated panel targets the 2009 H1N1 with more specificity and sensitivity. *For Research Use Only. Not for use in diagnostic procedures. PDM 2009 H1N1 Signatures Licensed from the CDC** LGC Biosearch Technologies is a licensed manufacturer of oligonucleotides to resolve the genetic signatures of the 2009 H1N1 pandemic. This panel consists of dual-labeled BHQ® probes, a forward primer, and a reverse primer for use in real-time PCR to discriminate novel influenza A H1N1 from other viral strains. PDM 2009 H1N1 ValuPanel Reagents contain probes and primers based on the following genetic signatures: Universal Influenza A PDM Influenza A (Swine Flu Specific) PDM H1 (Swine Flu Specific) Human RNase P (Extraction Control) These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the 2009 H1N1 diagnostic test. **CDC does not endorse products or services How is PDM 2009 H1N1 Different than the Original 2009 H1N1 ValuPanel Reagents? Improved Specificity – the new probes and primers target more conserved regions of the same genes that were resolved in the original panel. They are therefore appropriate for detection of diverse isolates of Novel Influenza A H1N1 that emerged internationally, while discriminating against other flu types and strains. Improved Sensitivity – PDM 2009 H1N1 ValuPanel Reagents were developed for detection of fewer copies of Novel Influenza A.

ValuPanel™试剂*由RT-qPCR的探针和引物组成，用于不同病原菌株的遗传鉴定。 *仅供研究使用。不用于诊断程序。 获CDC授权的甲型流感病毒亚型鉴定** 作为被授权的鉴定甲型流感亚型（季节性流感）的寡核苷酸制造商，LGC Biosearch提供所有主要流感病毒株的检测鉴定试剂，这些试剂Panel由用于qPCR的双标记BHQ探针、正向引物和反向引物组成，能够区分不同流感亚型的序列。甲型流感ValuPanel试剂含有基于以下菌株的遗传鉴定的探针和引物： 甲型（A）流感和乙型（B）流感 甲型流感亚型H1、H3和H5 人类RNase P（提取对照） 这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物均采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 ** CDC不认可产品或服务。 ValuPanel™ Reagents are composed of probes and primers for RT-qPCR to resolve the genetic signatures of different pathogen strains. LGC Biosearch Technologies is pleased to introduce Influenza A subtyping to the catalog of ValuPanel Reagents*. *For Research Use Only. Not for use in diagnostic procedures. Influenza A Subtyping Signatures Licensed from the CDC** As a licensed manufacturer of oligonucleotides to resolve influenza A subtypes (seasonal flu), LGC Biosearch is pleased to provide these important reagents for the detection of all major strains of influenza. This panel consists of dual-labeled BHQ® probes, a forward primer, and a reverse primer for use in real-time qPCR, to discriminate the sequences of influenza subtypes. Influenza A ValuPanel Reagents contain probes and primers based on genetic signatures for the following strains: Influenza A and Influenza B Influenza A subtypes H1, H3, and H5 Human RNase P (Extraction Control) These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the Influenza A subtyping panel. **CDC does not endorse products or services.

ValuPanel™试剂*由RT-qPCR的探针和引物组成，用于不同病原菌株的遗传鉴定。 *仅供研究使用。不用于诊断程序。 获CDC授权的甲型流感病毒亚型鉴定** 作为被授权的鉴定甲型流感亚型（季节性流感）的寡核苷酸制造商，LGC Biosearch提供所有主要流感病毒株的检测鉴定试剂，这些试剂Panel由用于qPCR的双标记BHQ探针、正向引物和反向引物组成，能够区分不同流感亚型的序列。甲型流感ValuPanel试剂含有基于以下菌株的遗传鉴定的探针和引物： 甲型（A）流感和乙型（B）流感 甲型流感亚型H1、H3和H5 人类RNase P（提取对照） 这些探针用FAM和Black Hole Quencher（BHQ）染料标记。所有探针和引物均采用HPLC纯化。LGC Biosearch是BHQ染料的发明者，并且是目前在标记探针上使用真正的黑暗猝灭剂BHQ的制造商。 ** CDC不认可产品或服务。 ValuPanel™ Reagents are composed of probes and primers for RT-qPCR to resolve the genetic signatures of different pathogen strains. LGC Biosearch Technologies is pleased to introduce Influenza A subtyping to the catalog of ValuPanel Reagents*. *For Research Use Only. Not for use in diagnostic procedures. Influenza A Subtyping Signatures Licensed from the CDC** As a licensed manufacturer of oligonucleotides to resolve influenza A subtypes (seasonal flu), LGC Biosearch is pleased to provide these important reagents for the detection of all major strains of influenza. This panel consists of dual-labeled BHQ® probes, a forward primer, and a reverse primer for use in real-time qPCR, to discriminate the sequences of influenza subtypes. Influenza A ValuPanel Reagents contain probes and primers based on genetic signatures for the following strains: Influenza A and Influenza B Influenza A subtypes H1, H3, and H5 Human RNase P (Extraction Control) These probes are labeled with FAM and Black Hole Quencher® (BHQ®) dyes. All probes and primers are HPLC purified. LGC Biosearch is the inventor of the BHQ dyes and is the sole manufacturer of the true dark quencher currently used for the labeled probes in the Influenza A subtyping panel. **CDC does not endorse products or services.